Evogene (NASDAQ:EVGN) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.04), MarketWatch Earnings reports. The firm had revenue of $0.64 million for the quarter. Evogene had a negative net margin of 1,147.40% and a negative return on equity of 33.97%.
Shares of Evogene stock opened at $1.92 on Friday. Evogene has a 12 month low of $1.98 and a 12 month high of $4.11.
Institutional investors have recently made changes to their positions in the company. Jane Street Group LLC purchased a new position in shares of Evogene during the fourth quarter valued at $71,000. ARK Investment Management LLC increased its stake in shares of Evogene by 45.0% during the third quarter. ARK Investment Management LLC now owns 242,570 shares of the biotechnology company’s stock valued at $754,000 after buying an additional 75,223 shares during the period. Vanguard Group Inc. increased its stake in shares of Evogene by 11.0% during the third quarter. Vanguard Group Inc. now owns 514,089 shares of the biotechnology company’s stock valued at $1,599,000 after buying an additional 50,823 shares during the period. Finally, Vanguard Group Inc increased its stake in shares of Evogene by 11.0% during the third quarter. Vanguard Group Inc now owns 514,089 shares of the biotechnology company’s stock valued at $1,599,000 after buying an additional 50,823 shares during the period. Hedge funds and other institutional investors own 35.37% of the company’s stock.
WARNING: This story was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.com-unik.info/2019/03/15/evogene-evgn-announces-earnings-results.html.
Evogene Company Profile
Evogene Ltd., a biotechnology company, engages in developing various products for various life science markets through the use of computational predictive biology platform. It discovers and develops products in various areas, including ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions, and human microbiome-based therapeutics.
Featured Article: What is the Dow Jones Industrial Average (DJIA)?
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.